# Enliven Therapeutics (ELVN) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ELVN
## Company Profile
- Ticker: ELVN
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 57.92 USD
- Market cap: 2163343681.92 USD
- Last updated: 2026-08-12
## Business Overview
### Precision Oncology
Enliven Therapeutics develops small-molecule precision medicines intended to improve both survival and quality of life for people with cancer.
### ELVN-001
ELVN-001 is a selective BCR::ABL1 tyrosine-kinase inhibitor for chronic myeloid leukemia. It is designed to retain antileukemic activity while reducing off-target effects associated with existing therapies.
### Late-Stage Development Path
Clinical development is moving from Phase 1 evaluation toward the pivotal ENABLE-2 program, positioning ELVN-001 as the company's principal potential registrational asset.
## Why The Stock Is Moving

As of Aug 12, 2026, ELVN closed down 1.46% at $57.92. No new same-company headline was identified in the current news window.

## Future Catalysts

- Phase 1 data update for ELVN-001 around mid-2026.
- Initiation of the Phase 3 ENABLE-2 trial in the second half of 2026.

## Drug Assets

- ELVN-001

## Recent News
- 2026-08-05 20:05 EST — [Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update](https://biopharmsignal.com/news/ELVN/enliven-therapeutics-reports-second-quarter-financial-results-and-provides-a-bus-6fd7af1f) — Source: Enliven Therapeutics
- 2026-06-15 20:40 EST — [Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares](https://biopharmsignal.com/news/ELVN/enliven-therapeutics-announces-closing-of-upsized-public-offering-of-common-stoc-18f4fdad) — Source: Enliven Therapeutics
- 2026-06-12 02:39 EST — [Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants](https://biopharmsignal.com/news/ELVN/enliven-therapeutics-announces-pricing-of-upsized-public-offering-of-common-stoc-f72b0424) — Source: Enliven Therapeutics
- 2026-06-11 20:05 EST — [Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants](https://biopharmsignal.com/news/ELVN/enliven-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre--4c0b4cdc) — Source: Enliven Therapeutics
- 2026-06-11 12:00 EST — [Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components](https://biopharmsignal.com/news/ELVN/enliven-therapeutics-announces-updated-positive-phase-1-clinical-data-and-alignm-72798101) — Source: Enliven Therapeutics